The Role of Lpd-Nanoparticles Containing Recombinant Major Surface Glycoprotein of Leishmania (Rgp63) in Protection Against Leishmaniasis in Murine Model Publisher Pubmed



Firouzmand H¹ ; Sahranavard M^{1, 2} ; Badiee A^{2, 3} ; Khamesipour A⁴ ; Alavizadeh SH^{2, 3} ; Samiei A⁵ ; Soroush D¹ ; Tavassoti Kheiri M⁶ ; Mahboudi F⁶ ; Jaafari MR^{1, 2, 3} Show Affiliations
Source: Immunopharmacology and Immunotoxicology Published:2018

Abstract

Context: Leishmaniasis is a major public health problem. Despite numerous attempts, yet there is no effective vaccine against human leishmaniasis, mainly due to a lack of an effective vaccine delivery system as well as adjuvant. Objective(s): The aim of this study was to evaluate the ability of recombinant glycoprotein 63 (rgp63) as a model of Leishmania antigen, entrapped in liposome–polycation–DNA (LPD) complexes nanoparticles in inducing cell mediated immune (CMI) response and protecting against L. major in BALB/c mice. Materials and methods: To this end, the abundant leishmania promastigote cell surface glycoprotein, gp63, was entrapped in nano-sized LPD (CpG) particles, (LPD (CpG)-rgp63), and BALB/c mice were immunized three times with either (LPD (CpG)-rgp63) or rgp63-CpG DNA or LPD (CpG) or free rgp63 and dextrose 5%. Various parameters including footpad thickness, splenic load of L. major parasites, rgp63-binding IgGs and also cytokine levels of rgp63-reactive T lymphocytes were then compared among different vaccinated animals. Results: The lowest number of parasites in spleen, the higher levels of IgG2a after challenge infection, the minimal footpad swelling and high level of IFN-γ secretion, all indicated that adjuvants and antigen-delivery systems are essential in modifying immune responses; as mice received LPD (CpG)-rgp63 induced immune response stronger than the other groups. Conclusions: This study demonstrates that LPD nanoparticle is a promising and adaptable delivery system which could be modified towards specific vaccine targets to induce a more potent immune response in combination with rgp63. © 2017 Informa UK Limited, trading as Taylor & Francis Group.